Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | An update on the experience with CAR T-cell therapy in China

He Huang • 16 Feb 2024
CAR-T Meeting 2024
Leukemia Lymphoma Multiple Myeloma CAR-T

In this video, He Huang, MD, PhD, Zhejiang University School of Medicine, Zhejiang, China, provides an update on the experience with CAR T-cell therapy in China. Prof. Huang highlights that the number of clinical trials and the use of CAR-T in clinical practice is increasing, and he hopes that collaboration with European countries will further enhance the CAR-T field in China. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from He Huang

4:17
Novel CAR T-cell therapies for hematological malignancies: exploring new targets
He Huang • 16 Feb 2024
6:29
HSCT & CAR-T therapy during COVID-19: Chinese experience
He Huang • 2 Feb 2021
1:19
Managing CRS after anti-BCMA CAR-T for myeloma
He Huang • 17 May 2019
2:37
CAR-T cells for myeloma: experience from China
He Huang • 16 May 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals